Akebia Therapeutics and Keryx Biopharmaceuticals to merge in all-stock deal [MarketWatch]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: MarketWatch
Akebia Therapeutics and Keryx Biopharmaceuticals to merge in all-stock deal Akebia Therapeutics Inc. AKBA, -3.80% and Keryx Biopharmaceuticals Inc. KERX, -8.94% said Thursday they have agreed to merge in an all-stock deal that will create a company focused on chronic kidney disease. The companies said the new entity will have pro forma equity value of about $1.3 billion, assuming full conversion of outstanding Keryx convertible notes. The new company will be called Akebia Therapeutics Inc. Under the terms of the deal, Keryx shareholders will recieve 0.37433 common share of Akebia for each Keryx share owned. Akebia CEO John Butler will lead the combined company and Keryx will appoint the chairman of the board. The deal is expected to close by year-end. "Combining Akebia and Keryx is expected to create a sustainable, kidney disease-focused, therapeutic leader that is well positioned to be a partner of choice throughout the renal community and for companies with products for patien
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management [Seeking Alpha]Seeking Alpha
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
AKBA
Earnings
- 3/14/24 - Beat
AKBA
Sec Filings
- 4/23/24 - Form 8-K
- 4/16/24 - Form 8-K
- 3/28/24 - Form 8-K
- AKBA's page on the SEC website